Editas Medicine, Inc. (0IFK.L)
USD 1.05
(-7.12%)
USD 1.05
(-7.12%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 150.05 Million USD | -2.33% |
| 2022 | 153.64 Million USD | 24.06% |
| 2021 | 123.84 Million USD | -30.82% |
| 2020 | 179.01 Million USD | -27.36% |
| 2019 | 246.44 Million USD | 33.78% |
| 2018 | 184.22 Million USD | 11.53% |
| 2017 | 165.18 Million USD | 74.66% |
| 2016 | 94.57 Million USD | -59.32% |
| 2015 | 232.47 Million USD | 745.99% |
| 2014 | 27.48 Million USD | 547.5% |
| 2013 | 4.24 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 152.79 Million USD | 4.69% |
| 2024 Q1 | 145.94 Million USD | -2.74% |
| 2024 Q3 | 151.93 Million USD | -0.56% |
| 2023 Q2 | 142.03 Million USD | -3.13% |
| 2023 Q3 | 144.18 Million USD | 1.52% |
| 2023 Q4 | 150.05 Million USD | 4.07% |
| 2023 FY | 150.05 Million USD | -2.33% |
| 2023 Q1 | 146.63 Million USD | -4.56% |
| 2022 FY | 153.64 Million USD | 24.06% |
| 2022 Q4 | 153.64 Million USD | 32.13% |
| 2022 Q3 | 116.28 Million USD | 0.75% |
| 2022 Q2 | 115.41 Million USD | 4.6% |
| 2022 Q1 | 110.34 Million USD | -10.9% |
| 2021 Q2 | 142.51 Million USD | 0.16% |
| 2021 Q1 | 142.29 Million USD | -20.51% |
| 2021 Q3 | 130.22 Million USD | -8.63% |
| 2021 Q4 | 123.84 Million USD | -4.9% |
| 2021 FY | 123.84 Million USD | -30.82% |
| 2020 Q1 | 232.17 Million USD | -5.79% |
| 2020 Q2 | 228.7 Million USD | -1.49% |
| 2020 Q3 | 156 Million USD | -31.79% |
| 2020 FY | 179.01 Million USD | -27.36% |
| 2020 Q4 | 179.01 Million USD | 14.75% |
| 2019 FY | 246.44 Million USD | 33.78% |
| 2019 Q3 | 162.36 Million USD | -0.12% |
| 2019 Q2 | 162.56 Million USD | 0.5% |
| 2019 Q1 | 161.75 Million USD | -12.2% |
| 2019 Q4 | 246.44 Million USD | 51.78% |
| 2018 Q2 | 162.19 Million USD | 3.66% |
| 2018 Q3 | 163.18 Million USD | 0.61% |
| 2018 FY | 184.22 Million USD | 11.53% |
| 2018 Q4 | 184.22 Million USD | 12.9% |
| 2018 Q1 | 156.46 Million USD | -5.27% |
| 2017 Q3 | 161.33 Million USD | -12.24% |
| 2017 FY | 165.18 Million USD | 74.66% |
| 2017 Q1 | 188.58 Million USD | 99.4% |
| 2017 Q2 | 183.84 Million USD | -2.51% |
| 2017 Q4 | 165.18 Million USD | 2.38% |
| 2016 Q3 | 71.97 Million USD | 15.58% |
| 2016 Q4 | 94.57 Million USD | 31.4% |
| 2016 Q2 | 62.27 Million USD | 31.25% |
| 2016 Q1 | 47.44 Million USD | -79.59% |
| 2016 FY | 94.57 Million USD | -59.32% |
| 2015 Q1 | - USD | -100.0% |
| 2015 FY | 232.47 Million USD | 745.99% |
| 2015 Q4 | 232.47 Million USD | 623.57% |
| 2015 Q3 | 32.12 Million USD | -9.55% |
| 2015 Q2 | 35.52 Million USD | 0.0% |
| 2014 Q4 | 27.48 Million USD | 0.0% |
| 2014 FY | 27.48 Million USD | 547.5% |
| 2013 FY | 4.24 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| uniQure N.V. | 624.01 Million USD | 75.953% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -18.999% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | 75.708% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | 43.318% |
| bluebird bio, Inc. | 424.62 Million USD | 64.661% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -118.235% |
| Imunon, Inc. | 8.53 Million USD | -1659.068% |
| IQVIA Holdings Inc. | 20.56 Billion USD | 99.27% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | 95.719% |
| Myriad Genetics, Inc. | 312.9 Million USD | 52.043% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 85.28% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 69.217% |
| Verastem, Inc. | 71.18 Million USD | -110.797% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 99.782% |
| Waters Corporation | 3.47 Billion USD | 95.684% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | 99.711% |
| Biogen Inc. | 12.04 Billion USD | 98.754% |
| Nektar Therapeutics | 267.04 Million USD | 43.809% |
| Perrigo Company plc | 6.04 Billion USD | 97.516% |
| Dynavax Technologies Corporation | 375.02 Million USD | 59.988% |
| Illumina, Inc. | 4.36 Billion USD | 96.563% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -326.573% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | 23.338% |
| Heron Therapeutics, Inc. | 256.47 Million USD | 41.494% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -302.381% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 92.061% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -82.034% |
| Evolus, Inc. | 209.68 Million USD | 28.438% |
| Adicet Bio, Inc. | 37.12 Million USD | -304.246% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -273.032% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 97.889% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 77.291% |
| FibroGen, Inc. | 585.72 Million USD | 74.381% |
| Agilent Technologies, Inc. | 4.91 Billion USD | 96.949% |
| OPKO Health, Inc. | 622.47 Million USD | 75.894% |
| Homology Medicines, Inc. | 118.53 Million USD | -26.594% |
| Geron Corporation | 146.12 Million USD | -2.689% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 96.295% |
| Exelixis, Inc. | 678.44 Million USD | 77.882% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -647.626% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -1097.192% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | 40.171% |
| Zoetis Inc. | 9.29 Billion USD | 98.386% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | 62.227% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -205.141% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 97.086% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -209.745% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 94.236% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 93.761% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -30.697% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 90.903% |
| Blueprint Medicines Corporation | 918.64 Million USD | 83.665% |
| Insmed Incorporated | 1.66 Billion USD | 90.97% |
| TG Therapeutics, Inc. | 169.08 Million USD | 11.254% |
| Incyte Corporation | 1.59 Billion USD | 90.576% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | 87.343% |